Related Experiment Video
Updated: May 7, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
The TAC1 Gene in Candida albicans: Structure, Function, and Role in Azole Resistance: A Mini-Review
Amir Hossein Mahdizade1,2, Akbar Hoseinnejad2,3, Mona Ghazanfari4,5
1Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract:
Candidiasis is a common fungal infection caused by Candida species, with Candida albicans being the most prevalent. Resistance to azole drugs, commonly used to treat Candida infections, poses a significant challenge. Transcriptional activator candidate 1 (TAC1) gene has emerged as a key player in regulating drug resistance in C. albicans. This review explores the structure and function of the TAC1 gene and its role in azole resistance. This gene encodes a transcription factor that controls the expression of genes involved in drug resistance, such as efflux pump genes (CDR1, CDR2, and MDR1) and ERG11. Mutations in TAC1 can increase these genes' expression and confer resistance to azoles. Various TAC1 gene mutations, mostly gain-of-function mutations, have been identified, which upregulate CDR1 and CDR2 expression, resulting in azole resistance. Understanding the mechanisms of azole resistance mediated by the TAC1 gene is crucial for the strategies in the effective antifungal development pipeline.
Insights
The TAC1 gene regulates azole drug resistance in Candida albicans by controlling efflux pump genes. Understanding TAC1 mutations is key to developing new antifungal treatments for candidiasis.
Area of Science:
- Mycology
- Molecular Biology
- Antimicrobial Resistance
Background:
- Candidiasis, a fungal infection caused by Candida species, is prevalent globally.
- Azole drugs are primary treatments for candidiasis, but resistance is a growing concern.
- The Transcriptional Activator Candidate 1 (TAC1) gene is implicated in Candida drug resistance.
Purpose of the Study:
- To review the structure and function of the TAC1 gene.
- To elucidate the role of TAC1 in azole resistance in Candida albicans.
- To highlight the significance of TAC1-mediated resistance mechanisms for antifungal drug development.
Main Methods:
- Literature review of studies on TAC1 gene function and azole resistance.
- Analysis of gene expression data related to TAC1 and drug resistance markers.
- Examination of identified TAC1 mutations and their impact on azole susceptibility.
Main Results:
- The TAC1 gene encodes a transcription factor regulating efflux pump genes (CDR1, CDR2, MDR1) and ERG11.
- Gain-of-function mutations in TAC1 upregulate CDR1 and CDR2 expression, conferring azole resistance.
- Specific TAC1 mutations are directly linked to increased resistance to azole antifungal agents.
Conclusions:
- The TAC1 gene is a critical regulator of azole resistance in Candida albicans.
- Understanding TAC1-mediated resistance mechanisms is essential for designing effective antifungal strategies.
- Targeting TAC1 or its downstream pathways may offer new avenues for combating candidiasis.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Gene Regulation in Microbial Communities: Quorum Sensing

